...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Journal of Clinical and Diagnostic Research >Anticancer Drug Induced PalmarPlantar Erythrodysesthesia
【24h】

Anticancer Drug Induced PalmarPlantar Erythrodysesthesia

机译：抗癌药诱发手掌红斑感觉异常

获取原文
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Background: Palmar plantar erythrodysesthesia (PPE) is a dose limiting toxicity of anticancer agents. In some cases it may mandate for discontinuation of anticancer agents. Evaluation of data of PPE among reported adverse drug reactions (ADRs) from the Department of Medical Oncology could quantify the burden.Aim: To evaluate and analyse the PPE among reported ADRs from medical Oncology.Materials and Methods: The data of all cases of reported PPE were collected during January 2012 to September 2013 and were analysed with WHO causality assessment scale. The severity was clinically graded. The follow-up data regarding outcome of ADRs were also noted.Results: During the study period of 21 months a total of 1418 ADRs have been reported from 1076 patients. Among them PPE was reported from 31 cases (2.9%). Majority (32.2%) of these patients were on chemotherapy for breast cancer. Patient?s age ranged from 17 to 68 y and the median age was 50 y. There were 18 female (58%) and 13 male patients (42%). Capecitabine was the leading drug involved in PPE, reported with 20 cases (64.5%), and followed by docetaxel with 5 cases (16.1%). Majority (67.7%) of the reactions was categorized as certain and 64.5% was grade II severity clinically.Conclusion: Our findings show that PPE accounts for 2.9% of total reported ADRs from Medical Oncology during 21 months. Majority of the reactions were classified as certain. Capecitabine is commonly implicated drug.
机译：背景：掌底红斑感觉不良（PPE）是抗癌药的剂量限制性毒性。在某些情况下，可能要求停用抗癌药。评估医学肿瘤学部门报告的药物不良反应（ADR）中的PPE数据可以量化负担。目的：评价和分析医学肿瘤学报告的ADR中的PPE材料和方法：所有报告病例的数据在2012年1月至2013年9月期间收集了个人防护装备，并用WHO的因果关系评估量表进行了分析。严重程度按临床分级。结果：在21个月的研究期间，共报告了1076例患者的1418例ADR。其中31例报告了PPE（2.9％）。这些患者中的大多数（32.2％）接受了化疗以治疗乳腺癌。患者的年龄为17至68岁，中位年龄为50岁。有18位女性（58％）和13位男性（42％）。卡培他滨是参与PPE的主要药物，报告20例（64.5％），其次是多西他赛5例（16.1％）。在临床上，大多数反应（67.7％）被归为肯定反应，而64.5％为II级严重。结论：我们的发现显示，在21个月内，PPE占医学肿瘤学报告的ADR的2.9％。大多数反应被确定为肯定的。卡培他滨是通常涉及的药物。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号